On November 13, 2025, Ensysce Biosciences, Inc. entered into a Securities Purchase Agreement for a direct offering of 1,513 Series B Preferred Shares and up to 665,922 Common Shares, raising approximately $1.7 million to support corporate purposes, including development projects. This event is significant and has a neutral sentiment.